CD14 is a well-characterized cell-activating receptor for lipopolysaccharide-binding protein (LBP) and peptidoglycan. It is an important modulator for lipopolysaccharide (LPS)-dependent signaling and is a component of the multi-protein complex containing also containing MD2 and toll-like receptor 4 (TLR4). CD14 is an important component of the innate immune response preferentially expressed on mature cells of monocyte lineage. The CD14 protein contains eleven leucine-rich repeats (LRRs). It is also known to be involved in the apoptotic cell clearance, cell surface adhesion molecule upregulation, and IgE level regulation. It exists in two forms: a glycosylphosphatidylinositol-anchored membrane protein (mCD14) and a monocyte or liver-derived soluble serum protein (sCD14) which lacks the anchor. sCD14 plays a role in LPS sensitivity to cells lacking the membrane form, and its increased expression is thought to be associated with inflammatory infectious diseases.
-Flow%20Cytometry-NBP2-25194-img0001.jpg)
Flow Cytometry: CD14 Antibody
Detailed immunological studies with the CD14 antibody from Funda’s lab indicate that human intestinal epithelial cells can both express and release soluble CD14 and may play a role in pathogenesis of endotoxin shock in the interplay between the mucosal immune system and bacteria1. Another group used the CD14 antibody in their secretome mapping of cancer cell lines and the Human Protein Atlas2. Wu’s group from Taiwan created and mined a comprehensive cancer cell secretome to test the utility and efficiency of such a system. Of the 31,000+ proteins initially detected, 94 potential cancer markers were identified and represent a focused reservoir of potential biomarkers. Studies out of the Estruch lab employed the CD14 antibody in immunoblotting assays to elucidate the role of transducers like toll-like receptor 2 (TLR2) and TLR4 in electronegative low-density lipoprotein-promoted inflammation3.
Novus Biologicals offers CD14 reagents for your research needs including:
PMIDs
